GlycoMimetics Initiates Dosing in Phase 1 Clinical Trial of GMI-1359
- First-in-Humans Study of Third GlycoMimetics Drug Candidate
"Our preclinical data points to the potential of GMI-1359 to inhibit the
growth and metastasis of a variety of cancers. We believe this is due to
a novel mechanism of action provided by inhibiting both E-selectin and
CXCR4 simultaneously," said
The randomized, double-blind escalating dose study is being conducted at
a single site in
Previous preclinical research has been shared via oral and poster
presentations at the annual meetings of both the
About
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics' planned activities with respect to the clinical
development of its drug candidate GMI-1359. Actual results may differ
materially from those indicated by such forward-looking statements as a
result of various important factors, including the availability and
timing of data from ongoing clinical trials, the uncertainties inherent
in the initiation of future clinical trials, whether interim results
from a clinical trial will be predictive of the final results of the
trial or results of early clinical trials will be indicative of the
results of future trials, expectations for regulatory approvals,
availability of funding sufficient for GlycoMimetics' foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
other matters that could affect the availability or commercial potential
of GlycoMimetics' drug candidates and other factors discussed in the
"Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that
was filed with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160906005729/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media